Clinical Trials Logo

Clinical Trial Summary

To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02614612
Study type Interventional
Source Incyte Corporation
Contact
Status Completed
Phase Phase 1
Start date December 2015
Completion date August 2018

See also
  Status Clinical Trial Phase
Completed NCT03112603 - A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Phase 3
Completed NCT03139604 - GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease Phase 3
Completed NCT02953678 - A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) Phase 2
Approved for marketing NCT03147742 - An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Approved for marketing NCT05722912 - Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD